Tag

Blood Cancer Therapy

All articles tagged with #blood cancer therapy

health2 years ago•1 min saved

FDA Greenlights Pfizer's Breakthrough Blood Cancer Treatment

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Pfizer's therapy, Elrexfio, for the treatment of difficult-to-treat multiple myeloma, a type of blood cancer. Elrexfio is a bispecific antibody therapy that helps the immune system kill cancer cells. Pfizer estimates the therapy could generate over $4 billion in peak revenue. The FDA approval is based on positive results from a mid-stage study, and Pfizer will continue testing the therapy in late-stage trials. Other similar antibody therapies in the market include Roche's Columvi, Abbvie's Epkinly, and Johnson & Johnson's Talvey.

via Reuters|

#blood-cancer-therapy #elrexfio #fda-approval

healthcare2 years ago•1 min saved

FDA Greenlights Johnson & Johnson's Breakthrough Blood Cancer Treatment

The U.S. FDA has granted approval to Johnson & Johnson's antibody-based therapy, Talvey, for the treatment of relapsed multiple myeloma, a difficult-to-treat type of blood cancer. Talvey is a bispecific antibody that brings together cancer cells and immune cells to enhance the body's immune response against cancer. The therapy will be priced at $45,000 per month, with an estimated treatment cost ranging from $270,000 to $360,000. Talvey is the first of its kind to target the protein GPRC5D, which is predominantly found in cancerous plasma cells. The approval comes with a boxed safety warning regarding potential immune response and neurologic toxicity.

via Reuters|

#bispecific-antibodies #blood-cancer-therapy #fda

healthcare2 years ago•1 min saved

FDA approves new bispecific antibody for blood cancer treatment.

The FDA has approved AbbVie and Genmab's blood cancer therapy, Epkinly, for adult patients who have received at least two prior lines of treatment. The therapy treats a type of advanced large B-cell lymphoma and is the first-of-its-kind to be approved by the FDA for the disease. The list price of Epkinly is $37,500 per month, and it is expected to reach $2.75 billion in peak sales globally. The therapy is being co-developed by AbbVie and Genmab as part of a $750 million deal made in 2020 to jointly develop and commercialize three of Genmab's cancer-targeting antibody products.

via Reuters|

#abbvie #blood-cancer-therapy #epkinly